Preclinical effects of highly potent MEK1/2 inhibitors on rat cerebral vasculature after organ culture and subarachnoid haemorrhage

Conclusion: The PD0325901 treatment did not improve the neurological score after SAH, nor showed any beneficial therapeutic effect on the contractility, contrasting with the reduction in neurological deficits seen after trametinib treatment. These data show that trametinib might be a potential candidate for treatment of SAH.

Source: Clinical Science - August 5, 2019 Category: Biomedical Science Authors: Christensen, S. T., Haanes, K. A., Spray, S., Grell, A.-S., Warfvinge, K., Edvinsson, L., Johansson, S. E. Tags: PublishAheadOfPrint Source Type: research